Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy
10.3969/j.issn.1674-8115.2017.06.019
- VernacularTitle:嵌合抗原受体T细胞疗法及其在血液肿瘤免疫治疗中的应用
- Author:
Li XIA
;
Yueying WANG
- Keywords:
chimeric antigen receptor T-cell immunotherapy;
hematological malignancies;
cellular immunotherapy
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(6):822-829
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) immunotherapy is a new type of immunotherapy,which has been developed rapidly in recent years.By using gene recombination and transfection techniques,CAR-modified effector T cells that specially recognize tumor-associated antigen was produced,which show better properties of targeting,killing activity and durability than conventional T cells.With the development of translational medicine research,CAR-T technology has experienced four generations of optimization and innovation,and presented a promising clinical efficacy in the treatment of various cancers,especially hematological malignancies.However,there are also potential risks with clinical use of this new technology,such as the off-target effect and cytokine storm.In this review,the progress,side effects,coping strategy,and development prospects of CAR-T in hematological malignancies immunotherapy were discussed.
